4-Dimethylaminomethyl-cyclohexanol | 102450-56-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-Dimethylaminomethyl-cyclohexanol
• 英文别名: 4-((Dimethylamino)methyl)cyclohexan-1-ol；4-[(dimethylamino)methyl]cyclohexan-1-ol
• CAS: 102450-56-6
• 化学式: C₉H₁₉NO
• 分子量: 157.256
• InChiKey: OJIDTYMSKQELNH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2,6-二氯-4-[(二甲基氨基)甲基]苯酚盐酸盐 在 水 、 铂 作用下， 生成 4-Dimethylaminomethyl-cyclohexanol
  参考文献：
  名称：

  The Use of Substituted Phenols in the Mannich Reaction and the Dehalogenation of Aminomethylhalophenols

  摘要：

  DOI：

  10.1021/jo01090a008

文献信息

• [EN] NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS<br/>[FR] NOUVELLES QUINAZOLINES À SUBSTITUTION BENZYLAMINO ET LEURS DÉRIVÉS EN TANT QU'INHIBITEURS DE SOS1
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2018115380A1

  公开（公告）日：2018-06-28

  The present invention encompasses compounds of formula (I), wherein the groups R1 to R7 have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.

  本发明涵盖了式（I）的化合物，其中基团R1至R7具有权利要求和说明中给定的含义，它们作为SOS1的抑制剂的用途，包含这种化合物的药物组合物以及它们作为药物/医疗用途的用途，特别是作为治疗和/或预防肿瘤疾病的药剂。
• CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS
  申请人：Sunovion Pharmaceuticals Inc.

  公开号：EP1976513B1

  公开（公告）日：2016-08-24
• [EN] CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS<br/>[FR] CYCLOALKYLAMINES INHIBITEURS DU RECAPTAGE DES MONOAMINES
  申请人：SEPRACOR INC

  公开号：WO2007081857A2

  公开（公告）日：2007-07-19

  [EN] The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.
  [FR] L'invention concerne de nouveaux dérivés de cyclohéxylamine et leur utilisation dans le traitement et/ou la prévention des troubles du système nerveux central (SNC), tels que la dépression, l'anxiété, la schizophrénie et les troubles du sommeil, ainsi que des procédés de synthèse de ceux-ci. L'invention concerne également des compositions pharmaceutiques contenant les composés de l'invention, ainsi que des procédés d'inhibition du recaptage des monoamines endogènes, telles que la dopamine, la sérotonine et la norépinéphrine de la fente synaptique, et des procédés de modulation d'un ou de plusieurs transporteurs de monoamines.